Wykorzystanie baz danych Narodowego Funduszu Zdrowia przy ocenie dowodów naukowych z praktyki klinicznej

Przemysław Holko,

Paweł Kawalec

Abstrakt

The use of the National Health Fund databases as a source of real-world evidence

Patient medical records and administrative healthcare databases are possible sources of real-world evidence (RWE), i.e., evidence on the potential benefits and risks of a medical product. RWE can complement the evidence from randomized clinical trials. The wide range of information collected by the National Health Fund (NFZ) and the Ministry of Health in Poland ensures the versatility of the data that cover almost all patients treated in Poland. In addition to administrative data (without detailed information about patients and their disease), electronic medical records of some patient groups can be obtained from special programs (e.g., KOS-Zawał) or the System of Monitoring Drug Programs (SMPT). Low usage (only 37 studies) but high usability of NFZ databases as a source of RWE were identified. Joint analysis of data from administrative databases and SMPT can increase the credibility of the study, but limits the study to only patients treated within the Drug Programs.

Słowa kluczowe: bazy danych, Narodowy Fundusz Zdrowia, dowody naukowe z praktyki klinicznej / databases, National Health Fund, real-world evidence
References

1. ISPOR. 2022-2023 Top 10 HEOR Trends Report, 2022, https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends (dostęp: 12.05.2022).

2. Gavrielov-Yusim N., Friger M., Use of Administrative Medical Databases in Population-based Research, "Journal of Epidemiology and Community Health" 2014; 68 (3): 283-287.

3. Zarebska-Michaluk D., Jaroszewicz J., Rogalska M., et al., Effectiveness of Tocilizumab With and Without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study, "Journal of Inflammation Research” 2021; 14: 3359-3366.

4. Offord C., The Surgisphere Scandal: What Went Wrong? Scientist, październik 2020, https://www.the-scientist.com/features/thesurgisphere-scandal-what-went-wrong—67955 (dostęp: 12.05.2022).

5. How Real World Evidence Was Used to Support Approval of Ibrance for Male Breast Cancer, "The Cancer Letter” 2019; 45: 7-10, https://cancerletter.com/the-cancer-letter/20190419_2/ (dostęp: 20.02.2022).

6. Flatiron Health, Flatiron Health Real-World Data Support FDA Approval of New Dosing Regimen for ERBITUX® (Cetuximab), komunikat prasowy, https://flatiron.com/press/press-release/flatiron-health-real-world-data-support-fdaapproval-of-new-dosingregimen-for-erbitux-cetuximab/ (dostęp: 20.02.2022).

7. EMA, Assessment Report on Provisional Measures - Zinbryta6 March 2018 EMA/159031/2018https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta (dostęp: 20.02.2022).

8. Narodowy Fundusz Zdrowia, Sprawozdania z działalności NFZhttps://www.nfz.gov.pl/bip/dzialalnosc-nfz/ (dostęp: 25.03.2022).

9. Holko P., REQUIREMENT-IBD: Real-World Consequences of Biologic Treatments for Inflammatory Bowel Diseases Based on the Analysis of the Databases of the National Health Fund, doi: 10.17605/OSF.IO/WQBRN.

10. Holko P., Kawalec P., Pilc A., Cost-Effectiveness Analysis of Crohns Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist, "Pharmacoeconomics” 2018; 36 (7): 853-865.

11. Zagórowicz E., Walkiewicz D., Kucha P., et al., Epidemiology of Inflammatory Bowel Disease in Poland 2009-2020: Nationwide Data, "Polish Archives of Internal Medicine” 2022, doi: 10.20452/pamw.16194.

12. Holko P., Kawalec P., Stawowczyk E., Prevalence and Drug Treatment Practice of Inflammatory Bowel Diseases in Poland in the Years 2012-2014 - An Analysis of Nationwide Databases, "European Journal of Gastroenterology and Hepatology” 2018; 30 (4): 456-464.

13. Tuśnio N., Fichna J., Nowakowski P., Comparison of the Efficacy of Available Statistical Methods for Prediction of the Hospitalizations Number: Proof of Concept and Validation Based on the Analysis of Polish National Health Fund Data in The Years 2009-2017, "Folia Medica Cracoviensia” 2019; 59 (1): 89-100.

14. Holko P., Kawalec P., Pilc A., Impact of Biologic Treatment of Crohns Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland, "Frontiers in Pharmacology” 2018; 9: 621.

15. Kaniewska M., Moniuszko A., Rydzewska G., The Efficacy and Safety of the Biosimilar Product (Inflectra®) Compared to the Reference Drug (Remicade®) in Rescue Therapy in Adult Patients with Ulcerative Colitis, "Przegląd Gastroenterologiczny”2017; 12 (3): 169-174.

16. Eder P., Kłopocka M., Wiśniewska-Jarosińska M., et al., Possible Undertreatment of Women with Crohn Disease in Poland. A Subgroup Analysis from a Prospective Multicenter Study of Patients on Anti-Tumor Necrosis Factor Therapy, "Polish Archives of Internal Medicine” 2017; 127 (10): 674-680.

17. Stawowczyk E., Kawalec P., Pilc A., Cost-Utility Analysis of 1-Year Treatment with Adalimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland, "European Journal of Clinical Pharmacology” 2016 Nov; 72 (11): 1319-1325.

18. Stawowczyk E., Kawalec P., Pilc A., Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland, "Pharmacotherapy” 2016 May; 36 (5): 472-481.

19. Kubielas G., Diakowska D., Uchmanowicz I., Survival Analysis of Patients with Acute Coronary Syndrome Receiving Comprehensive Coordinated Care after Myocardial Infarction (KOS-Zawał), "Kardiologia Polska” 2022; 80 (3): 415-321, doi: 10.33963/KP.a2022.0035.

20. Januszewicz W., Witczak K., Wieszczy P., et al., Prevalence and Risk Factors of Upper Gastrointestinal Cancers Missed During Endoscopy: A Nationwide Registry-Based Study, "Endoscopy” 2022; 54 (7): 653-660, doi: 10.1055/a-1675-4136.

21. Kostera-Pruszczyk A., Napiórkowski Ł., Szymańska K., et al., Spinal Muscular Atrophy: Epidemiology and Health Burden in Children - A Polish National Healthcare Database Perspective Before Introduction of SMA-Specific Treatment, "Neurologia i Neurochirurgia Polska” 2021; 55 (5): 479-484, doi: 10.5603/PJNNS.a2021.0074.

22. Pietrzykowski Ł., Kasprzak M., Michalski P., et al., The Influence of Patient Expectations on Adherence to Treatment Regimen after Myocardial Infarction, "Patient Education and Counseling” 2022; 105 (2): 426-431, doi: 10.1016/j.pec.2021.05.030.

23. Kardas P., Urbański F., Lichwierowicz A., et al., Prevalence and Age Structure of Polypharmacy in Poland: Results of the Analysis of the National Real-World Database of 38 Million Citizens, "Frontiers in Pharmacology” 2021; 12: 655364, doi: 10.3389/fphar.2021.655364.

24. Wilk M., Waśko-Grabowska A., Skoneczna I., et al., Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study, "Frontiers in Oncology” 2021; 11: 664741, doi: 10.3389/fonc.2021.664741.

25. Wyszomirska K., Wyszomirski A., Brzeziński M., et al., Home Artificial Nutrition in Polish Children: An Analysis of 9-Year National Healthcare Provider Data, "Nutrients” 2021; 13 (3): 1007. Published 2021 Mar 21, doi: 10.3390/nu13031007.

26. Deja M.A., Malinowski M., Widenka K., et al., Repair or Replacement for Secondary Mitral Regurgitation: Results From Polish National Registry, "Annals of Thoracic Surgery” 2022; 113 (1): 146-156, doi: 10.1016/j.athoracsur.2020.12.059.

27. Tomasik A., Nabrdalik K., Kwiendacz H., et al., Effect of Diabetes Mellitus and Left Ventricular Perfusion on Frequency of Development of Heart Failure and/or All-cause Mortality Late After Acute Myocardial Infarction, "American Journal of Cardiology” 2021; 140: 25-32, doi: 10.1016/j.amjcard.2020.10.051.

28. Kapica-Topczewska K., Collin Fz., Tarasiuk J., et al., John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis, "European Journal of Neurology” 2020; 83 (5): 487-492, doi: 10.1159/000510849.

29. Wita K., Kułach A., Sikora J., et al., Managed Care after Acute Myocardial Infarction (MC-AMI) Reduces Total Mortality in 12-Month Follow-Up-Results from a Polands National Health Fund Program of Comprehensive Post-MI Care-A Population-Wide Analysis, "Journal of Clinical Medicine” 2020; 9 (10): 3178, doi: 10.3390/jcm9103178.

30. Pietrzykowski Ł., Michalski P., Kosobucka A., et al., Medication Adherence and its Determinants in Patients After Myocardial Infarction, "Scientific Reports” 2020; 10 (1): 12028, doi: 10.1038/s41598-020-68915-1.

31. Kozioł M., Nowak M.S., Udziela M., et al., First Nation-Wide Study of Diabetic Retinopathy in Poland in the Years 20132017, "Acta Diabetologica” 2020; 57 (10): 1255-1264, doi: 10.1007/s00592-020-01540-6.

32. Wita K., Kułach A., Wita M., et al., Managed Care After Acute Myocardial Infarction (KOS-Zawał) Reduces Major Adverse Cardiovascular Events by 45% in 3-Month Follow-Up - Single-Center Results of Polands National Health Fund Program of Comprehensive Post-Myocardial Infarction Care, "Archives of Medical Science” 2019; 16 (3): 551-558, doi: 10.5114/aoms.2019.85649.

33. Kapica-Topczewska K., Collin F., Tarasiuk J., et al., Clinical and Epidemiological Characteristics of Multiple Sclerosis Patients Receiving Disease-Modifying Treatment in Poland, "Neurologia i Neurochirurgia Polska” 2020; 54 (2): 161-168, doi: 10.5603/PJNNS.a2020.0020.

34. Małyszczak A., Łukawska A., Dyląg I., et al., Blood Platelet Count at Hospital Admission Impacts Long-Term Mortality in Patients with Acute Coronary Syndrome, "Cardiology” 2020; 145 (3): 148-154, doi: 10.1159/000505640.

35. Zuber-Laskawiec K., Kubicka-Trzaska A., Karska-Basta I., et al., Non-Responsiveness and Tachyphylaxis to Anti-Vascular Endothelial Growth Factor Treatment in Naive Patients with Exudative Age-Related Macular Degeneration, "Journal of Physiology and Pharmacology” 2019; 70 (5): 10.26402/jpp.2019.5.13, doi: 10.26402/jpp.2019.5.13.

36. Wierzba W., Wierzba A., Śliwczyński A., et al., Analysis of National Health and Insurance Registers for All-Cause Mortality in Patients with Heart Failure with and without Diabetes Mellitus in Poland in 2012, "Medical Science Monitor” 2019; 26:e921138, doi: 10.12659/MSM.921138.

37. Brzozowska M., Wierzba W., Śliwczyński A., et al., Analysis of the Survival of Patients Receiving Systemic Treatment for Melanoma of the Skin: A Retrospective Population Study with Patients Treated in Poland in 2011-2015, "Postępy Dermatologii i Alergologii” 2019; 36 (4): 438-441, doi: 10.5114/ada.2019.83368.

38. Brzozowska M., Wierzba W., Szafraniec-Buryło S., et al., Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland, "Medical Science Monitor” 2019; 25: 3846-3853, doi: 10.12659/MSM.914517.

39. Bandurska E., Damps-Konstańska I., Popowski P., et al., Cost-Effectiveness Analysis of Integrated Care in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD), "Medical Science Monitor” 2019; 25: 2879-2885, doi: 10.12659/MSM.913358.

40. Brzozowska M., Wierzba W., Szafraniec-Buryło S., et al., Overall Survival of Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated with Erlotinib, Gefitinib or Afatinib Under Drug Programmes in Poland - Real-World Data, "Archives of Medical Science” 2019; 17 (6): 1618-1627, doi: 10.5114/aoms.2018.80362.

41. Symonides B., Śliwczyński A., Gałązka Z., et al., Short- and Long-Term Survival After Open Versus Endovascular Repair of Abdominal Aortic Aneurysm-Polish Population Analysis, "PLoS One” 2018; 13 (6): e0198966, doi: 10.1371/journal.pone.0198966.

42. Tłustochowicz M., Śliwczyński A.M., Brzozowska M., et al., Sequentiality of Treatment in the Rheumatoid Arthritis Drug Programme in the Years 2009-2014, "Archives of Medical Science” 2018; 14 (3): 569-571, doi: 10.5114/aoms.2016.58924.

43. Szyluk K., Jasiński A., Niemiec P., et al., Male Gender and Age Range 20-29 Years Are the Most Important Non-Modifiable Risk Factors for Recurrence After Primary Post-Traumatic Shoulder Dislocation, "Knee Surgery, Sports Traumatology, Arthroscopy”2018; 26 (8): 2454-2464, doi: 10.1007/s00167-018-4924-4.

44. Tomasik A., Młyńczak T., Nowak E., et al., Quantitative Myocardial Blush Score (QuBE) Allows the Prediction of Heart Failure Development in Long-Term Follow-Up in Patients With ST-Segment Elevation Myocardial Infarction: Proof of Concept Study, "Journal of Cardiology” 2019; 26 (4): 322-332, doi: 10.5603/CJ.a2017.0129.

45. Brzozowska M., Wierzba W., Śliwczyński A., et al., Analysis of Survival of Patients Treated with Vemurafenib, Ipilimumab and Dabrafenib for Advanced Skin Melanoma in Daily Clinical Practice (Real-World Data): Retrospective Analysis of Patients Treated Under Drug/Reimbursement Programmes In Poland In 2013-2016, "Melanoma Research” 2018; 28 (1): 52-55, doi: 10.1097/CMR.0000000000000408.

46. Jacheć W., Tomasik A., Polewczyk A., et al., Impact of ICD Lead on the System Durability, Predictors of Long-Term Survival Following ICD System Extraction, "Pacing and Clinical Electrophysiology” 2017; 40 (10): 1139-1146, doi: 10.1111/pace.13173.

47. Gąsior M., Pres D., Wojakowski W., et al., Causes of Hospitalization and Prognosis in Patients with Cardiovascular Diseases. Secular Trends in the Years 2006-2014 According to the Silesian Cardiovascular (SILCARD) Database, "Polish Archives of Internal Medicine” 2016; 126 (10): 754-762, doi: 10.20452/pamw.3557.

48. Kozierkiewicz A., Jach R., Basta T., et al., Skuteczność i koszty leczenia raka jajnika w PoIsce - ujęcie regionalne [Efficacy and Costs of Ovarian cCancer Therapy in Poland - Regional Approach], "Ginekologia Polska” 2015; 86 (8): 582-589.

49. Kubica A., Obońska K., Kasprzak M., et al., Prediction Of High Risk Of Non-Adherence To Antiplatelet Treatment, "Kardiologia Polska” 2016; 74 (1): 61-67, doi: 10.5603/KP.a2015.0117.

50. Opolski G., Januszkiewicz Ł., Szczerba E., et al., Readmissions and Repeat Procedures after Catheter Ablation for Atrial Fibrillation, "Journal of Cardiology” 2015; 22 (6): 630-636, doi: 10.5603/CJ.a2015.0037.

51. Śliwczyński A., Brzozowska M., Iltchew P., et al., Epidemiology of Asthma in Poland in Urban and Rural Areas, Based on Provided Health Care Services, "Pneumonologia i Alergologia Polska” 2015; 83 (3): 178-187, doi: 10.5603/PiAP.2015.0029.

52. Gierlotka M., Zdrojewski T., Wojtyniak B., et al., Incidence, Treatment, In-Hospital Mortality and One-Year Outcomes of Acute Myocardial Infarction in Poland in 2009-2012 - Nationwide AMI-PL Database, "Kardiologia Polska” 2015; 73 (3): 142-158, doi: 10.5603/KP.a2014.0213.

53. Sielski J., Janion-Sadowska A., Sadowski M., et al., Differences in Presentation, Treatment, and Prognosis in Elderly Patients with NonSTSegment Elevation Myocardial Infarction, "Polish Archives of Internal Medicine” 2012; 122 (6): 253-261, doi: 10.20452/pamw.1285.

54. Przybysz-Zdunek B., Ploch M., Pluta W., et al., All-cause Readmission and Repeat Revascularization after Percutaneous Coronary Intervention, "Journal of Cardiology” 2012; 19 (2): 174-179, doi: 10.5603/cj.2012.0030.